Attendee search 

MergerMotives GmbH - The M&A Consulting Boutique

"Customized support for Mergers & Acquisitions, In- and Outlicensing, Business Development and other related areas".

We are a small and specialized M&A consulting boutique with a young and innovative mindset that is advising and supporting its clients in Mergers & Acquisitions, In- and Outlicensing, Business Succession, Business Development and other related areas. Our clients are companies from various industries all around the world that either do not have their own Business Development team or that need some additional temporary resources for their M&A team.

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and the EU, with a robust pipeline of 30 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and the EU. Luye Pharma is a global cutting edge company in terms of research into new drug delivery technologies, such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.

Luye Pharma has set up 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. The company offers more than 30 products covering the 4 largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, with business conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., the EU and Japan, as well as fast growing emerging markets.

BMG Pharma is involved in the development of new healthcare products in the areas of oral care, dermatology including aesthetics, anaemia, osteoarthritis & cancer supportive care.

The company has created a strong portfolio of intellectual property which it has developed into a number of products that have been partnered with companies around the world.

The company recently merged with Sigea,an Italian company with expertise in targeted functional ingredients development currently focused on modified sodium hyaluronate for application in a number of therapeutic areas including dermatology and oral care. This merger will allow BMG to accelerate the development of a number of new products to complement its portfolio.